Robert Dolski
Director of Finance/CFO chez AUTOLUS THERAPEUTICS PLC
Profil
Robert Dolski's current job is as the Chief Financial Officer & Senior Vice President at Autolus Therapeutics Plc.
Formerly, he worked as the Senior Director-Finance at FORUM Pharmaceuticals, Inc. from 2013 to 2016.
Prior to that, he was the Vice President-Finance & Treasury at Human Genome Sciences, Inc. from 2007 to 2012.
He also served as the Chief Financial Officer at Checkmate Pharmaceuticals, Inc. In addition, Mr. Dolski held the position of Chief Financial & Accounting Officer at Akcea Therapeutics, Inc. in 2020.
He was also the Vice President, Head-Financial Planning & Analysis at Moderna, Inc. from 2016 to 2019.
Mr. Dolski completed his undergraduate studies at the University of Pennsylvania and obtained an MBA from The Wharton School of the University of Pennsylvania.
Postes actifs de Robert Dolski
| Sociétés | Poste | Début |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Director of Finance/CFO | 07/08/2023 |
Anciens postes connus de Robert Dolski
| Sociétés | Poste | Fin |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Director of Finance/CFO | 18/05/2020 |
| MODERNA, INC. | Corporate Officer/Principal | 01/05/2019 |
FORUM Pharmaceuticals, Inc.
 FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Corporate Officer/Principal | 01/06/2016 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/12/2012 |
| CHECKMATE PHARMACEUTICALS, INC. | Director of Finance/CFO | - |
Formation de Robert Dolski
| University of Pennsylvania | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| MODERNA, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
